Tricida Inc. Common Stock
(NASDAQ:TCDA)
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
TCDA Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$9.4000 |
Previous Close Volume |
191200 |